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A comparison between the novel rabbit monoclonal antibodies (SP1 and B644) and mouse antibodies for evaluating estrogen receptor in breast tumors
Uma comparação entre os novos anticorpos monoclonais de coelho (SP1 e B644) e anticorpos de camundongo para detecção de receptores de estrógeno em carcinomas mamários ) using a tissue microarray of breast carcinomas. Methods: Two cylinders (2 mm diameter) of formalin-fixed paraffin embedded tissue were obtained from 24 invasive breast carcinomas and immunostained by using the anti-ER rabbit and mouse antibodies and the streptavidin-biotin detection system (Biogenex ® ). Immunostaining was evaluated considering positive those tumors in which more than 10% of the tumor cell nuclei stained. The stain intensity was also evaluated as weak (1), moderate (2), and strong (3) . Results: Both rabbit antibodies against ER have similar staining pattern to each other and also to 6F11, but significantly stronger scores compared to mouse 1D5. The rabbit antibodies allow better cost/benefit because of higher working dilutions compared to mouse antibodies using the same procedure. 
Introduction
Estrogen receptor (ER) may be the best example of a tumor biomarker with an assay that drives therapeutic decision-making (7, 17) . Since 1990, pathology has played an important role not only in diagnosis, but also by providing additional information about prognostic and predictive molecular markers aimed at the best breast cancer treatment (22) .
Although predictive factors of therapy response have more clinical value, the only broadly validated predictive factors for routine clinical use are ER and progesterone receptor (PR) (2) . Since the release of monoclonal and polyclonal antibodies that react in formalin-fixed paraffinembedded tissue, scientists have been evaluating ER almost exclusively by immunohistochemistry (1, 5, 8, 19, 25) . Several different methods and different antibodies against ER have been used for immunohistochemistry testing. As a result, there is not yet a universally accepted standard (16, 23) . As with any laboratory method, technical details have a great effect on the final result (11, 20, 21) .
The most used antibodies for ER evaluation by immunohistochemistry have been the mouse monoclonal antibodies. Recently, a new generation of rabbit monoclonal antibodies has been developed (14) . The technology to prepare these antibodies from a single hybridoma allows the production of antibodies with high sensitivity and specificity, high working dilutions and better cost versus benefits. According to the suppliers, the novel rabbit monoclonal antibodies could replace the mouse monoclonal antibodies because of their high specificity, lower cost, and faster technical procedure, which would not require an antigen retrieval step (3, 14, 24) . Several anti-ER antibodies have been used in clinical and research immunohistochemical testing, including mouse monoclonal antibodies. Clones 6F11 and 1D5 have been compared in clinical studies and were shown to have similar sensitivities (28) . Studies have also compared 1D5 with a novel rabbit monoclonal, SP1 (15, 24) , which has eight-fold higher affinity (15) . Another study showed that SP1 is more sensitive than 1D5 for detecting ER expression in breast cancer, in both a duplicate-redundancy 431-sample TMA, and in 121 whole sections of clinical materials from multiple institutions (27) .
In the present study, we compared sensitivity and cost/ benefit between the novel rabbit monoclonal antibodies and two most used mouse monoclonal antibodies, developing the antigen retrieval step in all immunohistochemistry reactions for ER evaluation in invasive breast carcinomas.
Methods

Case selection
Twenty-four cases of invasive breast carcinomas diagnosed between 1990 and 2005 were randomly selected from the files of the breast pathology laboratory of the School of Medicine, Universidade Federal de Minas Gerais (UFMG), Brazil. All original slides were reviewed to confirm the diagnosis and to select representative areas of tumors. Two cylinders (2 mm diameter) of each tumor with representative areas of neoplasia were selected from paraffin blocks to build a tissue microarray (TMA). Two cylinders of tumor from previously tested positive and negative tumors were also included as internal controls for TMA. Sequential 5 µm sections were obtained and stained for hematoxylin and eosin (first and last sections) to confirm diagnosis, and interval sections were used for the immunohistochemical study. Slides containing sections of a positive breast tumor were included in all batches as external control.
Immunohistochemical study
The sections were mounted on glass slides coated with silane (3-aminopropyltriethoxysilane) and dried for 30 minutes at 37°C. Then, they were deparaffinized in xylene and rehydrated via a series of graded alcohols. Endogenous peroxidase activity was blocked by incubating the sections in a methanol bath containing 3% hydrogen peroxide for 20 min, followed by washing in distilled water. All sections were initially submitted to heat-induced epitope retrieval using citrate buffer (pH 6.0). After that, the primary antibody was applied and incubated for 90 minutes at room temperature. Mouse monoclonal antibodies (1D5 and 6F11) and rabbit monoclonal antibodies (SP1 and B644) were used in order to evaluate ER and PR (Table 1) . Preliminary testing was performed in our laboratory to identify the best concentration for each antibody, and to choose the negative and positive controls using the dilution data supplied by the manufacturer as the starting point. A dilution of 1:300 was used for both rabbit antibodies and 1:100 for both mouse antibodies. After washing primary antibody with phosphate buffered saline (PBS), the slides were incubated with linking biotinylated antibody (Biogenex ® ) for 20 min. The sections were rinsed with PBS, followed by incubation with peroxidase-conjugated streptavidin complex for 20 min (Super Sensitive Link-Label Immunohistochemical Detection System, Biogenex ® ). Table 1 Evaluation of estrogen receptor in 24 breast cancers using two rabbit monoclonal antibodies (SP1 and B644) and mouse monoclonal antibodies (1D5 and 6F11) Cases rabbit Mouse SP1 B644 1D5 6F11   1  1  2  2  3  2  2  1  1  2  3  0  0  0  0  4  3  2  2  3  5  0  0  0  0  6  3  3  2  3  7  2  2  1  2  8  3  3  3  3  9  2  2  0  2  10  3  3  3  3  11  0  0  0  0  12  0  0  0  0  13  2  2  1  1  14  0  0  0  0  15  3  3  3  3  16  3  3  3  3  17  3  3  3  3  18  3  3  1  2  19  0  0  0  0  20  0  0  0  0  21  1  1  0  1  22  0  0  0  0  23  3  3  2  3 Freshly prepared diaminobenzidine (DAB) solution (1 drop of 3, 3'-diaminobenzidine tetrahydrochloride for 1 ml of substrate, DAKO ® ) was applied for two minutes on each section. DAB was removed by rinsing with distilled water. The slides were counterstained with hematoxylin, dehydrated in ethanol, cleared in xylene and mounted using Entelan ® .
Immunostaining analysis
All slides submitted to immunohistochemistry were coded, and the examiner was blinded to the antibody used. The cut offs were those most used in literature (8) (9) (10) . We considered positive those tumors containing more than 10% of stained nuclei, independent of the staining intensity. If a difference of staining was observed, the strongest staining hot spot of the two discs of each tumor was considered in the analysis. The intensity of the reaction and the background were also evaluated as negative (0) or positive: weak (1), moderate (2), and strong (3).
Statistical analysis
The Wilcoxon test was used in the comparative statistical analysis of the different antibodies positivity and the Spearman coefficient was used to evaluate if there was a positive correlation among the different antibodies.
results
After developing the immunohistochemistry staining including the antigen retrieval step, the analysis of the ER stained sections generated scores that are shown in Tables 1 and 2 , and in Figure 1 . Estrogen receptor evaluation was positive in 15 cases (62.5%), with variable staining intensity among the different cases and antibodies used. In five cases (8, 10, 15, 16, and 17) , there was no variation in the intensity of staining using the different clones, and tumor cells showed strong reactivity. In two cases (9 and 21) there was positive reaction for both rabbit antibodies and mouse 6F11 and negative reaction for mouse 1D5. Nine cases (37.5%) were negative for all antibodies tested.
There was a statistically significant difference when comparing clone 1D5 to both rabbit antibodies and to mouse 6F11, which stained stronger (p < 0.05). However, no difference was observed between the stains of both rabbits and mouse 6F11. Besides, they showed the highest agreement (Figure 1) .
Time of storage of the paraffin blocks, which ranged from one to 15 years, had no effect on staining intensity and positivity.
The costs of each test (in US$) of all antibodies are shown on Table 3 . Table 2 Number of positive and negative cases and percentages (in parenthesis) according to staining intensity for each antibody tested against estrogen receptor Staining intensity rabbit Mouse SP1 B644 1D5 6F11 
Discussion
I n t h e p r e s e n t s t u d y w e c o m p a r e d t h e immunohistochemistry staining of the novel rabbit monoclonal antibodies SP1 and B644 with mouse monoclonal antibodies 1D5 and 6F11 for ER testing in breast carcinomas using TMA and the same immunohistochemical method and antigen retrieval. There are few other studies in literature comparing the novel rabbit monoclonal antibodies to mouse antibodies (3, 4, 24) and no studies comparing both rabbit antibodies. Cano et al. (3) evaluated ER and PR in fine-needle aspirates and paraffin-embedded sections from breast cancers using SP1 and SP2 rabbit antibodies. They nuclei. However, other investigators excluded the intensity of staining, as it has been shown to have no relationship to therapy response or prognosis (1, 8, 12, 18, 26) .
Although the suppliers of the rabbit monoclonal antibodies advocate that the total reaction time can be shorter by avoiding the epitope retrieval step, pretests performed in our laboratory showed that the working dilution was 1:50 when antigen retrieval was not used, whereas a dilution of 1:300 was achieved when using epitope retrieval. Although the antigen retrieval step is more time-consuming, the total cost of each test dropped six times when this technique was used in our slides. Other authors used rabbit monoclonal SP1 10 times less concentrated than 6F11, when using antigen retrieval. They also described that acceptable staining was obtained with SP1 even in the absence of antigen retrieval, but 6F11 sensitivity dropped dramatically (24) . In our experience, comparison among the costs of each test for each antibody showed that the rabbit monoclonal antibodies present lower cost per test due to their higher working dilutions. However, if the recommended dilution supplied by the manufacturers had been used, the cost per test would be quite similar for the different antibodies. According to Huang et al. (14) , who did not perform antigen retrieval step, the high affinity of clone SP1 and its binding to a different epitope from clone 1D5 would explain why antigen retrieval is not necessary. Rabbit monoclonal antibody SP1 has appropriate tissue reactivity, with nuclear staining in epithelial tissues of known ER status, showing an affinity eight times higher than that of 1D5 and reactivity with the predicted band on Western blotting (15) .
Huang et al. (15) also demonstrated that SP1 showed similar results to mouse clone 1D5, in all but six out of 61 samples. According to the authors, clone SP1 may be more sensitive than clone 1D5 and has the same specificity as clone 1D5 in immunohistochemistry (15) . In summary, the new rabbit monoclonal antibodies against ER (SP1 and B644) are highly sensitive, showing a stronger and sharper immunohistochemistry signal, and reliable in immunohistochemical testing of breast carcinomas. Both ER rabbit antibodies allowed better cost/benefit because of higher working dilutions compared to mouse 1D5 and 6F11 and are sensitive and reliable for clinical and research testing.
found that the use of rabbit monoclonal antibodies against ER and PR on alcohol-fixed smears and paraffin sections provided several advantages, such as high sensitivity and specificity of the reaction, stronger immunostaining, shorter procedure times, and avoidance of antigen retrieval step. Rossi et al. (24) carried out a comparative study between rabbit clones against estrogen and progesterone receptors, Ki67, cyclin D1, CD3, CD5, CD23, and synaptophysin and classic mouse monoclonal antibodies against the same antigens on several tumor types as well as normal tissues. They found no significant differences in the percentage of positive cells and staining intensity. However, the authors suggest that the rabbit antibodies appear to offer increased sensitivity with no apparent loss of specificity and also allowed a higher working dilution. Cheuk et al. (6) compared the novel rabbit anticyclin D1 to the mouse antibodies against cyclinD1 and considered that the rabbit antibody SP4 showed superior performance over the mouse monoclonal antibody. A consistent immunostaining for cyclin D1 was readily achieved when compared to mouse antibody DCS-6 in 150 cases of lymphoproliferative lesions (9) . Cheang et al. (4) evaluated immunohistochemistry using the new rabbit antibody SP1 and mouse antibody 1D5. They evaluated the relationship to biochemical ER assay results and clinical data on survival and adjuvant systemic therapy. The authors detected 69.5% of positivity when using the rabbit SP1 and 63.1% using the mouse antibody 1D5. Rabbit antibody SP1 was also a better independent prognostic factor than 1D5 in multivariate analysis, including age, tumor size, grade, and lymphovascular and nodal status. SP1 was considered, by these authors (4) , an improved standard for ER immunohistochemistry assessment in breast cancer. In our study, we considered the cut point of 10% for positivity. However, there is a variation of ER scoring interpretation in the literature, ranking from 1% to 10% considering or not the staining intensity. Harvey et al. (13) demonstrated that patients whose tumors presented 1% or more ER-positive cells responded to antiestrogen therapy.
A semiquantitative evaluation of the intensity of staining was used in order to detect differences of sensitivity among the different antibodies. Many studies reported their results of ER and PR analysis based on a semiquantitative method considering both intensity and percentage of positive 
